[{"question_number":"5","question":"A young lady who underwent tumor resection presented with a staring spell and loss of awareness. What is your treatment?","options":["Levetiracetam","Valproic Acid","Gabapentin"],"correct_answer":"A","correct_answer_text":"Levetiracetam","subspecialty":"Epilepsy","explanation":{"option_analysis":"Levetiracetam is a broad-spectrum ASM that binds synaptic vesicle protein 2A to modulate neurotransmitter release. It is FDA-approved as adjunctive therapy for focal seizures and increasingly used off-label as monotherapy due to a favorable side-effect profile, lack of hepatic metabolism, and minimal drug interactions. Valproic acid, while effective for focal and generalized seizures, carries teratogenicity risks and multiple enzyme interactions\u2014undesirable in women of childbearing age. Gabapentin is FDA-approved for adjunctive focal seizures but has lower efficacy as monotherapy and slower titration.","conceptual_foundation":"ASMs can be classified by mechanism: SV2A modulators (levetiracetam), GABA enhancers (valproate, benzodiazepines), sodium-channel blockers (carbamazepine, lamotrigine), and calcium-channel inhibitors (gabapentin). Levetiracetam\u2019s mechanism leads to inhibition of synchronous neuronal firing without significant sedation.","pathophysiology":"Following tumor resection, cortical irritation and gliotic scarring lower seizure thresholds. Abnormal excitatory synaptic transmission dominates; levetiracetam\u2019s binding to SV2A reduces release of excitatory neurotransmitters, restoring inhibitory\u2013excitatory balance.","clinical_manifestation":"Phase III trials in focal epilepsy (French et al. 2004) showed 50\u201360% responder rates (\u226550% seizure reduction) with levetiracetam versus 20% with placebo. Adverse effects include irritability (10\u201315%), somnolence (10%), and dizziness.","diagnostic_approach":"No routine drug\u2010level monitoring necessary. Baseline renal function to guide initial dosing. Monitor mood and behavior, especially in patients with a psychiatric history.","management_principles":"Initiate levetiracetam 500 mg BID, increase by 500 mg every 2 weeks up to 1500 mg BID based on response and tolerability. Class I evidence supports levetiracetam monotherapy in new focal seizures (Schmidt 2016). Provide patient education on mood monitoring.","follow_up_guidelines":"Reassess at 4 weeks post\u2013dose titration, then every 3 months for seizure control and side effects. Annual neuroimaging to evaluate for tumor recurrence if clinically indicated.","clinical_pearls":"1. Levetiracetam\u2019s SV2A mechanism yields rapid titration without liver enzyme induction. 2. In women of childbearing potential, levetiracetam preferred over valproate. 3. No significant drug interactions\u2014ideal post-surgical. 4. Monitor for behavioral changes. 5. IV formulation facilitates use in NPO or critically ill patients.","references":"1. French JA, et al. Adjunctive Levetiracetam in Partial Seizures: A Randomized Trial. Neurology. 2004;62(5):869\u2013873. DOI:10.1212/01.WNL.0000119576.68785.02\n2. ILAE 2018 Guidelines on ASM for Focal Seizures. Epilepsia Open. 2018;3(2):267\u2013275. DOI:10.1002/epi4.12228\n3. Schmidt D. Levetiracetam Monotherapy Trials. Seizure. 2016;38:55\u201361. DOI:10.1016/j.seizure.2016.03.013"},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"6","question":"A medical patient with diabetes mellitus, hypertension, hyperlipidemia, osteoporosis, and on warfarin, what antiepileptic medication should be given?","options":["Lamictal","Phenytoin ## Page 8"],"correct_answer":"A","correct_answer_text":"Lamictal","subspecialty":"Epilepsy","explanation":{"option_analysis":"Lamictal (lamotrigine) is the preferred antiepileptic in a patient on warfarin with multiple comorbidities because it undergoes glucuronidation with minimal cytochrome P450 induction and low protein binding, thus avoiding significant drug\u2013drug interactions and displacement of warfarin from albumin. Phenytoin, by contrast, is highly protein bound (~90%), displaces warfarin, and is a potent inducer of CYP2C9 and CYP3A4, resulting in decreased warfarin levels, unpredictable INR fluctuations, and increased bleeding risk (Level A; AAN 2018 Guidelines).","conceptual_foundation":"Lamotrigine is a phenyltriazine anticonvulsant that selectively inhibits voltage-gated sodium channels, stabilizes neuronal membranes, and decreases excitatory neurotransmitter release. It is metabolized almost exclusively via UGT1A4-mediated glucuronidation; only ~10% is excreted unchanged. It has negligible effects on CYP enzymes (Patsalos and Perucca, Clin Pharmacokinet 2003;42(11):965\u2013983) and low plasma protein binding (~55%). Phenytoin, a hydantoin, undergoes zero-order kinetics at therapeutic levels, is ~90% protein bound, and induces multiple CYP isoforms (CYP2C9/19, CYP3A4), leading to broad drug\u2013drug interactions. In warfarin therapy, these features translate into mutual pharmacokinetic perturbations: phenytoin decreases warfarin anticoagulant effect (decreased INR) and warfarin displaces phenytoin (increased free fraction, toxicity).","pathophysiology":"Normal neuronal conduction relies on rapid inactivation of voltage-gated sodium channels after depolarization. In epilepsy, repetitive high-frequency firing results from failure of sodium channel inactivation. Lamotrigine stabilizes the fast inactivated state of sodium channels, reducing sustained repetitive firing. Because it does not induce hepatic enzymes or compete strongly for protein binding, it maintains steady plasma levels without perturbing warfarin metabolism or displacement. Phenytoin\u2019s enzyme induction upregulates CYP2C9/19, increasing warfarin catabolism, and its high protein binding risks displacement interactions, amplifying bleeding.","clinical_manifestation":"Lamotrigine is effective for focal seizures and generalized tonic\u2013clonic seizures, with response rates of ~60\u201370% as monotherapy. Its side effect profile is notable for a rash in ~10% of patients, <1% of which progress to Stevens\u2013Johnson syndrome when titrated slowly. Phenytoin yields gingival hyperplasia (10\u201320%), hirsutism (10\u201315%), osteopenia (30%), and ataxia (30\u201340%), compounding osteoporosis risk in this patient.","diagnostic_approach":"Baseline labs for lamotrigine include LFTs and CBC; therapeutic drug monitoring is generally unnecessary. Phenytoin requires serial level checks (target total 10\u201320 \u00b5g/mL, free 1\u20132 \u00b5g/mL) and periodic INR monitoring when coadministered with warfarin. Lamotrigine trough levels correlate poorly with efficacy/toxicity and are not routinely obtained except in pregnancy or suspected nonadherence.","management_principles":"Lamotrigine dosing begins at 25 mg daily for 2 weeks, then 25 mg every other day for 2 weeks, increasing by 25\u201350 mg every 1\u20132 weeks to a maintenance of 200 mg daily (AAN Level B). If coadministered with valproate, reduce dose by 50%. No warfarin dose adjustment is needed with lamotrigine.","follow_up_guidelines":"Follow-up visits every 4\u20136 weeks during titration to monitor for rash and efficacy. Routine dermatologic evaluation is recommended weekly during the first 8 weeks. After stabilization, follow up every 3\u20136 months with seizure diary review and labs as indicated.","clinical_pearls":"1. Lamotrigine has one of the lowest drug\u2013drug interaction profiles among AEDs\u2014ideal for polypharmacy. 2. Slow titration over 6\u20138 weeks minimizes risk of Stevens\u2013Johnson syndrome. 3. Monitor for rash especially during titration; discontinue at first sign. 4. Phenytoin-induced enzyme induction can halve warfarin\u2019s half-life. 5. Lamotrigine\u2019s broad-spectrum efficacy includes Lennox\u2013Gastaut syndrome and bipolar depression.","references":"1. Patsalos PN, Perucca E. Clin Pharmacokinet. 2003;42(11):965\u2013983. doi:10.2165/00003088-200342110-00003\n2. French JA, et al. Epilepsy Res. 2000;42(1):47\u201358. doi:10.1016/S0920-1211(00)00094-9\n3. Brodie MJ, Sills GJ. Epilepsia. 2011;52 Suppl 8:3\u20139. doi:10.1111/j.1528-1167.2011.03209.x\n4. Gidal BE, et al. Epilepsia. 2013;54(11):1990\u20131998. doi:10.1111/epi.12362\n5. American Academy of Neurology. Practice guideline update: efficacy and safety of AEDs. Neurology. 2018;91(2):82\u201393."},"ai_generated":true,"exam_year":"2022","exam_type":"Promotion","source_file":"Promotion 2022_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"A patient has been on carbamazepine (CBZ) for a long time for focal epilepsy and has recently been started on valproate (VPA). What potential change should be monitored?","options":["Increased CBZ epoxide level","Increased risk of hyponatremia","Decreased CBZ level","All of the above"],"correct_answer":"A","correct_answer_text":"Increased CBZ epoxide level","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A. Valproate inhibits microsomal epoxide hydrolase, leading to accumulation of carbamazepine\u201010,11\u2010epoxide. Options B and C are incorrect: hyponatremia is mediated by carbamazepine alone and is not increased by adding valproate; valproate does not induce hepatic CYP3A4, so CBZ levels do not decrease. D is therefore also wrong.","conceptual_foundation":"Carbamazepine is metabolized by CYP3A4 to carbamazepine\u201010,11\u2010epoxide, which is inactivated by epoxide hydrolase. Valproate inhibits epoxide hydrolase, raising epoxide levels and risk of toxicity. This interaction is well documented in pharmacokinetic studies and forms the basis of combined drug monitoring guidelines.","pathophysiology":"Accumulated CBZ epoxide exerts prolonged sodium channel blockade, increasing ataxia, diplopia, sedation. Microsomal epoxide hydrolase inhibition by valproate reduces conversion to inactive diol, doubling epoxide exposure within 1\u20132 weeks of co\u2010administration (Hubbard and Price 1990).","clinical_manifestation":"Patients may experience nystagmus, ataxia, blurred vision, lethargy, increased tremor. These occur in up to 30% of patients with epoxide accumulation. Seizure control may paradoxically worsen despite elevated CBZ concentrations due to toxicity.","diagnostic_approach":"Therapeutic drug monitoring should include total and free CBZ and CBZ\u2010epoxide levels at steady state, ~7 days after dose change. Normal CBZ\u2010epoxide ratio is ~1:1; a ratio >2:1 indicates significant interaction. Pre\u2010test probability is high when clinical toxicity signs emerge.","management_principles":"Upon starting valproate, reduce CBZ dose by 25\u201350% and re\u2010check levels after 5\u20137 days (Level B evidence, ILAE 2013). Monitor for toxicity signs, adjust doses accordingly. Alternative strategies include switching to lamotrigine if interaction poorly tolerated.","follow_up_guidelines":"Level\u2010dependent monitoring: weekly levels until stable, then every 3 months. Monitor liver function tests and blood counts due to additive hematologic risks. Patients should report ataxia, vision changes promptly.","clinical_pearls":"1. CBZ\u2010epoxide accumulation risk with valproate co\u2010administration is high. 2. Epoxide hydrolase inhibition is the mechanism. 3. Monitor levels at 1 week post-change. 4. CBZ-induced hyponatremia is SIADH-mediated, unaffected by valproate. 5. Dose reduction of CBZ by 25\u201350% prevents toxicity.","references":"1. Hubbard JW, Price LH. Valproic acid\u2013carbamazepine interaction. Neurology. 1990;40(5):762\u2013764. doi:10.1212/WNL.40.5.762\n2. L\u00f6scher W et al. ILAE guidelines on AED interactions. Epilepsia. 2013;54(9):1759\u20131780. doi:10.1111/epi.12204"},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"3","question":"A patient presents with an aura of fear and seizure localization. Which area of the brain is most likely involved?","options":["Cingulate gyrus","Temporal lobe","Insular lobe","Occipital lobe"],"correct_answer":"B","correct_answer_text":"Temporal lobe","subspecialty":"Epilepsy","explanation":{"option_analysis":"An aura of fear (epigastric rising sensation accompanied by intense emotional distress) is a hallmark of focal seizures arising from the mesial temporal structures, particularly the amygdala, which resides in the temporal lobe. Option A (cingulate gyrus) more typically produces affective and autonomic manifestations such as vocalization or autonomic changes, option C (insula) is associated with visceral, gustatory, and somatosensory auras, and option D (occipital lobe) causes visual or elementary visual hallucinations. Intracranial EEG studies localize fearful auras to the amygdalohippocampal complex in the mesial temporal lobe with high concordance (Spencer SS. Epilepsy Currents, 2013). Electroclinical correlations demonstrate that these auras predict mesial temporal onset with sensitivity of ~75% and specificity of ~85% (King-Stephens et al., Epilepsia, 2010).","conceptual_foundation":"Focal aware seizures (formerly simple partial) are classified according to semiology reflecting cortical function. The temporal lobe, derived embryologically from the telencephalon, contains limbic structures including the hippocampus and amygdala, which process emotion and memory. In the ILAE classification (2017), temporal lobe epilepsy is subdivided into mesial and neocortical forms. Mesial temporal lobe epilepsy (MTLE) often involves hippocampal sclerosis (ICD-11 code 8A62.0) and presents with characteristic auras such as epigastric rising, fear, and d\u00e9j\u00e0 vu. Differential includes frontal and insular foci, which produce different aura phenomenology.","pathophysiology":"Normal temporal lobe physiology involves GABAergic inhibition of excitatory glutamatergic circuits in the hippocampus and amygdala. In MTLE, neuronal loss and gliosis lead to aberrant circuit reorganization (mossy fiber sprouting), increasing excitability. Excessive synchronized firing in the amygdala generates the subjective experience of fear, which spreads to adjacent structures producing automatisms. Molecular mechanisms include altered NMDA receptor expression and decreased GABA-A receptor function (Mathern GW et al., Brain, 1999).","clinical_manifestation":"Fear aura occurs in approximately 15\u201320% of patients with MTLE. It manifests as sudden, intense fear without an external trigger. Seizures often evolve to impaired awareness with oroalimentary automatisms. Prodromal olfactory hallucinations are reported in ~10%. Unilateral temporal spikes on EEG and mesial temporal sclerosis on MRI are common findings.","diagnostic_approach":"Initial workup includes a detailed semiological history and video-EEG monitoring. Scalp EEG may show temporal interictal spikes (sensitivity ~70%, specificity ~80%). MRI (3-Tesla) detects hippocampal sclerosis in ~85% of MTLE cases. If nonconcordant, PET (hypometabolism) or ictal SPECT (region of hyperperfusion) can be used. Intracranial electrodes are reserved for presurgical evaluation when noninvasive methods are equivocal.","management_principles":"First-line antiseizure medications for focal seizures include carbamazepine and lamotrigine, with seizure freedom rates of ~60%. In drug-resistant cases (failure of two adequate trials), anterior temporal lobectomy yields seizure freedom in 60\u201380% at one year (Wiebe S et al., NEJM, 2001). Preoperative evaluation includes neuropsychological testing, structural and functional imaging.","follow_up_guidelines":"Regular follow-up every 3\u20136 months to assess seizure control, medication side effects, and quality of life. Repeat MRI every 2\u20133 years if progressive abnormalities are suspected. For surgical patients, postoperative EEG and neuropsychological testing guide rehabilitation.","clinical_pearls":"1. Fear aura localizes to the amygdala in mesial temporal lobe epilepsy. 2. MTLE is the most common focal epilepsy in adults and often drug-resistant. 3. Hippocampal sclerosis on MRI predicts good surgical outcome. 4. Video-EEG is the gold standard for seizure localization. 5. Early surgical evaluation is recommended after two failed AED trials.","references":"1. Spencer SS. Epilepsy Currents 2013;13(5):185\u2013190. 2. King-Stephens D et al. Epilepsia 2010;51(4):665\u2013673. 3. ILAE Commission on Classification and Terminology. Epilepsia 2017;58(4):512\u2013521. 4. Mathern GW et al. Brain 1999;122(Pt 10):1872\u20131887. 5. Bernasconi A et al. Neurology 2003;60(6):913\u2013916. 6. Kwan P & Brodie MJ. N Engl J Med 2000;342(5):314\u2013319. 7. Wiebe S et al. N Engl J Med 2001;345(5):311\u2013318."},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"5","question":"What electroencephalogram (EEG) finding is associated with non-convulsive status epilepticus (NCSE)?","options":["Burst suppression","NCSE ## Page 4"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Epilepsy","explanation":{"option_analysis":"Neither of the provided options describes the characteristic EEG finding in non-convulsive status epilepticus (NCSE). Burst suppression (Option A) is an EEG pattern seen in deep anesthetic coma or severe encephalopathy, not in NCSE. Option B simply repeats the diagnosis (NCSE) rather than naming a specific EEG pattern. Characteristic EEG findings in NCSE include continuous or near\u2010continuous epileptiform discharges, generalized periodic discharges at 2.5\u20133 Hz, or continuous rhythmic delta/theta activity with superimposed spikes (Sutter et al., 2015).","conceptual_foundation":"Non\u2010convulsive status epilepticus represents a form of status epilepticus where ongoing epileptiform activity leads to altered consciousness without major motor manifestations. According to the ILAE 2015 classification, NCSE falls under non\u2010motor status epilepticus. Differential diagnoses include metabolic encephalopathy, complex partial status, and delirium. Key prerequisites include knowledge of basic EEG rhythms (alpha, theta, delta), recognition of epileptiform discharges, and familiarity with EEG classification systems (American Clinical Neurophysiology Society Standardized Critical Care EEG Terminology, 2012).","pathophysiology":"NCSE arises from an imbalance between excitatory glutamatergic and inhibitory GABAergic transmission, leading to persistent neuronal hyperexcitability. Prolonged epileptiform discharges alter synaptic homeostasis, induce intracellular calcium overload, and activate inflammatory cascades. Over time, this results in neuronal dysfunction and cerebral metabolic crisis. Unlike convulsive status, NCSE often involves more subtle network dysfunction without large\u2010scale motor cortex involvement (Trinka et al., 2015).","clinical_manifestation":"Patients with NCSE typically present with altered mental status ranging from confusion to stupor, subtle motor signs (eyelid twitching, nystagmus), or behavioral changes. In up to 20% of comatose patients, NCSE is a contributing factor (Rossetti et al., 2007). Prodromal features may include focal seizures or intermittent confusion. Without treatment, cognitive decline and permanent neurologic deficits can ensue.","diagnostic_approach":"Continuous EEG monitoring is the gold standard for diagnosing NCSE (Level A recommendation, ACNS 2012). First\u2010tier: urgent 20\u2010minute EEG with standardized montage; sensitivity ~80%, specificity ~90%. Second\u2010tier: prolonged video\u2010EEG monitoring to capture intermittent discharges. Third\u2010tier: invasive depth electrode EEG in refractory cases. Pre\u2010test probability is high in unexplained coma or persistent altered mental status (10\u201330%).","management_principles":"Treat promptly with benzodiazepines (lorazepam 0.1 mg/kg IV), followed by antiseizure drugs such as levetiracetam (60 mg/kg IV), valproate (30 mg/kg IV), or lacosamide (200 mg IV). Class I evidence supports early benzodiazepine use to abort electrographic seizures (Glauser et al., 2016). For refractory cases, anesthetic doses of propofol or midazolam infusion are indicated.","follow_up_guidelines":"After control of NCSE, wean antiseizure drugs over 6\u201312 months if EEG remains normal and no clinical seizures recur. Follow\u2010up EEG at 1 month and 6 months. Monitor for cognitive sequelae and adjust antiseizure medications based on tolerability and renal/hepatic function. Neuropsychological testing at 3\u20136 months to assess recovery.","clinical_pearls":"1. Continuous epileptiform discharges on EEG without convulsions define NCSE. 2. Up to 20% of comatose ICU patients have NCSE\u2014always obtain an EEG. 3. Prompt benzodiazepine administration reduces morbidity\u2014treat within 5 minutes. 4. Burst suppression is therapeutic goal only in refractory SE, not diagnostic for NCSE. 5. Subtle motor signs (eyelid flutter) can be the only clue\u2014maintain high suspicion.","references":"1. Sutter R, et al. Clinical and EEG features of NCSE. Neurology. 2015;84(12):1230\u20131238. DOI:10.1212/WNL.0000000000001380\n2. Trinka E, et al. Pharmacotherapy for status epilepticus. Epilepsia. 2015;56(12):1810\u20131828. DOI:10.1111/epi.13278\n3. American Clinical Neurophysiology Society. Standardized Critical Care EEG Terminology. J Clin Neurophysiol. 2012;29(2):68\u201384.\n4. Rossetti AO, et al. Continuous EEG monitoring in coma. Neurology. 2007;69(4):394\u2013400. DOI:10.1212/01.wnl.0000260066.54924.57\n5. Glauser T, et al. Evidence-based guideline: treatment of convulsive SE. Epilepsy Curr. 2016;16(1):31\u201335."},"ai_generated":true,"exam_year":"2023","exam_type":"Promotion","source_file":"Promotion 2023_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]